Anavex Life Sciences Corp (AVXL)

[Investor2014]

So is Teva or Celgene more likely going to be our MS partner?

Celgene

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex®).

http://ir.celgene.com/releasedetail.cfm?releaseid=1027283


Teva

Our work in MS is not confined to Copaxone® and the relapsing forms of MS. Patients with progressive forms of the disease currently have no approved treatment options. We have an extensive research program investigating a new compound called laquinimod, which we believe has a neuro-protective capability. We are developing laquinimod for both relapsing and progressive forms of MS, in the hope that this new potential medicine will offer patients a much needed option in the treatment of progressive forms of MS.

http://www.tevapharm.com/research_development/rd_focus/multiple_sclerosis/

No reference to Biogen in the Lisak et al Abstract!